# Hansoh BioMedical R&D Company clinical trials: 48 (2026)

ClinicalTrials.gov lists 48 trials with Hansoh BioMedical R&D Company as lead sponsor, 33 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Hansoh BioMedical R&D Company: 48 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899086 | A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899086) |
| October 23, 2026 | NCT07892625 | A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892625) |
| October 19, 2026 | NCT07879885 | An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis | Hansoh BioMedical R&D Company | Phase 2 | Recruiting | Moderate-to-severe Plaque Psoriasis | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879885) |
| September 22, 2026 | NCT07834359 | A Study of HS-20197 in Participants With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Solid Tumors | 595 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834359) |
| September 17, 2026 | NCT07824882 | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or... | Hansoh BioMedical R&D Company | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824882) |
| September 16, 2026 | NCT07821606 | Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Platinum-sensitive Recurrent Ovarian Cancer | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821606) |
| August 20, 2026 | NCT07775703 | HS-20117-2 Injection in Patients With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Advanced Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775703) |
| June 12, 2026 | NCT07645222 | PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Lung Cancer | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645222) |
| June 2, 2026 | NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621601) |
| March 11, 2026 | NCT07464327 | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or... | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464327) |
| March 10, 2026 | NCT07462923 | HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Hansoh BioMedical R&D Company | Phase 1 | Active not recruiting | Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462923) |
| December 15, 2025 | NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | Hansoh BioMedical R&D Company | Phase 1/2 | Recruiting | CRC | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283367) |
| September 22, 2025 | NCT07186452 | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Advanced Solid Tumors | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186452) |
| September 18, 2025 | NCT07181343 | A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) | Hansoh BioMedical R&D Company | Phase 1 | Completed | Psoriasis (PsO) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181343) |
| August 11, 2025 | NCT07115446 | Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Advanced Prostate Cancer | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115446) |
| April 20, 2025 | NCT06936735 | A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Advanced Solid Tumor | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06936735) |
| April 20, 2025 | NCT06935409 | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Hansoh BioMedical R&D Company | Phase 3 | Completed | Osteosarcoma | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06935409) |
| April 15, 2025 | NCT06927570 | A Study of HS-20122 in Patients With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Advanced Solid Tumors | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06927570) |
| April 13, 2025 | NCT06926582 | A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis | Hansoh BioMedical R&D Company | Phase 2 | Not yet recruiting | Psoriasis | 305 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926582) |
| March 24, 2025 | NCT06892379 | A Study of HS-20110 in Participants With Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Solid Tumors | 475 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892379) |
| March 3, 2025 | NCT06855069 | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Hansoh BioMedical R&D Company | Phase 3 | Recruiting | Ovarian Cancer | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06855069) |
| February 25, 2025 | NCT06844799 | A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Moderate-to-severe Plaque Psoriasis | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06844799) |
| February 13, 2025 | NCT06825624 | ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Metastatic Colorectal Cancer (CRC) | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06825624) |
| January 8, 2025 | NCT06763159 | A Study of HS-20124 in Patients with Advanced Solid Tumors | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Solid Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06763159) |
| November 21, 2024 | NCT06699576 | ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Osteosarcoma, Soft Tissue Sarcoma (STS) | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699576) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 2 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 21 |
| Not yet recruiting | 12 |
| Unknown | 10 |
| Completed | 3 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Small Cell Lung Carcinoma | 4 |
| Psoriasis | 4 |
| Osteosarcoma | 3 |
| Glomerulonephritis, IGA | 2 |
| Ovarian Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Sarcoma | 2 |
| Carcinoma, Neuroendocrine | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Lung Neoplasms | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Neoplasm Metastasis | 1 |
| Esophageal Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Arthritis, Psoriatic | 1 |
| Neuromyelitis Optica | 1 |
| Myelodysplastic Syndromes | 1 |
| Anemia | 1 |
| Bone Marrow Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Elementary schools in the United States](https://specstream.ai/data/businesses/elementary-schools/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
